Moffitt Notice of Blackbaud Data Incident. Learn More
Clinical Trials Search
A Phase III, Multicneter, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Atezolizumab Given in Combination with Cabozantinib versus Cabozantinib Alone in Patients with Inoperable, Locally, Advanced, or Metastatic Renal Cell Carcinoma Who Experienced Radiographic Tumor Progression During or After Immune Checkpoint Inhibitor Treatment
This is a Phase III, multicenter, randomized, open-label study designed to evaluate the efficacy and safety of atezolizumab given in combination with cabozantinib versus cabozantinib alone in participants with inoperable, locally advanced, or metastatic renal cell carcinoma (RCC) who experienced radiographic tumor progression during or after Immune Checkpoint Inhibitor (ICI) treatment in the metastatic setting.
This study will evaluate the efficacy and safety of atezolizumab when given in combination with cabozantinib (Atezo; Cabo) compared with cabozantinib alone in patients with advanced clear cell or non;clear cell RCC (papillary or unclassified only) who experienced radiographic tumor progression during or after ICI treatment in the metastatic setting.
Atezolizumab (Tecentriq); Cabozantinib (XL 184)